Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was terminated on 16 November 2010 following a US FDA partial clinical hold for the tanezumab interstitial cystitis clinical study announced on 19 July 2010 for potential safety issues, and following a pre-planned interim analysis.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with interstitial cystitis/ painful bladder syndrome for more than 6 months with moderate to severe pain and a micturition frequency greater than 7 per day.
Patients who have been on stable oral medicines for interstitial cystitis/ painful bladder syndrome for at least 3 months. Other therapies might need to be stopped.
You may not be if
Patients on certain recent treatments for interstitial cystitis/ painful bladder syndrome.
Body mass index (BMI) of \>39 kg/m2.
History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.
Patients with peripheral neuropathy.
Patients with Type I or type II diabetes mellitus who have an HbA1c \> 8.0%.
Clareo Health | A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
